This fusion mutation is associated with the efficacy of specific cancer treatment (using tyrosine kinase inhibitor [TKI]), with an objective response rate of 85.7% with ALK-TKI in seven non-pulmonary solid tumors with CTNNA1-ALK or ITSN2-ALK fusion mutations for ALK (Table 2) 89. The gene discussed is ALK; the disease is cancer.